According to Financial Times, The 9 analysts offering 12 month price targets for Etsy Inc have a median target of 15.00, with a high estimate of 17.00 and a low estimate of 13.50.
The stock of Editas Medicine Incorporated (NASDAQ:EDIT) registered an increase of 9.47% in short interest. On average, equities research analysts expect that Editas Medicine will post ($3.05) EPS for the current year. Two analysts have provided estimates for Editas Medicine's earnings.
U.S. based company, Editas Medicine, Inc.
Editas Medicine received a price-target increase Thursday from Chardan Capital Markets after the genome-editing company announced late Wednesday the achievement of a second milestone under its collaboration with Juno Therapeutics (JUNO) amid technical progress toward overcoming the tumor microenvironment in a research program. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.62) by $0.23. Editas Medicine had a negative return on equity of 69.21% and a negative net margin of 2,091.36%. The average volume stands around 0.79 million shares. Nonetheless, from here on out, earnings per share forecasts for the current quarter are $-0.65. Editas Medicine's revenue was down 8.8% on a year-over-year basis.
Several other equities analysts have also issued reports on EDIT. Zacks Investment Research lowered Editas Medicine from a "buy" rating to a "hold" rating in a research note on Tuesday, July 18th. Oppenheimer Holdings, Inc. reiterated a "market perform" rating on shares of Editas Medicine in a research note on Tuesday, July 18th.
Russian stocks undermined by tensions between USA and N.Korea
The U.S. equity market is hovering near record levels and volume has been tepid following the onset of summer. Indexes: In London, the FTSE 100 moved down 0.6% to 7,452.24, and Spain's IBEX 35 gave up 0.3% at 10,563.60.
The company's consensus rating on Reuter's scale slipped from 1.71 to 1.62 during a month. Finally, SunTrust Banks, Inc. began coverage on Editas Medicine in a research report on Thursday, July 13th. They issued a "hold" rating and a $17.00 price target for the company. Five brokerage firms recommended the company shares with a hold recommendation, around three have issued a buy recommendation and 1 has released a strong buy recommendation to the firms shares. Editas Medicine now has an average rating of Buy and an average price target of $25.03.
How Active Are Editas Medicine, Inc. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of USA and global copyright and trademark law. The company had revenue of $3.10 million during the quarter, compared to the consensus estimate of $2.20 million.
In related news, insider Gerald Frank Cox purchased 4,000 shares of the company's stock in a transaction that occurred on Friday, June 2nd. The stock was acquired at an average cost of $14.15 per share, for a total transaction of $56,600.00. Following the purchase, the insider now owns 4,000 shares of the company's stock, valued at approximately $56,600. Also, Director Kevin Bitterman sold 1,000,000 shares of the stock in a transaction on Monday, May 22nd. The Stock becomes significant when you consider how many shares are shorted versus the average daily volume, means how many days to cover those short shares at that volume. Boris Nikolic, Director disclosed the purchase of 35,000 shares of (EDIT). Finally, ProShare Advisors LLC boosted its position in shares of Editas Medicine by 18.9% in the second quarter. Bank of America Corp DE now owns 5,936 shares of the company's stock valued at $133,000 after buying an additional 2,489 shares during the period. Paulson & CO. Inc. purchased a new stake in Editas Medicine during the first quarter worth about $1,116,000. Institutional investors own 67.87% of the company's stock. Schwab Charles Investment Management Inc. boosted its position in shares of Editas Medicine by 8.4% in the first quarter. 1,081,197 shares of the stock were exchanged. UBS Group AG has an ownership of 78,217 stocks of the firms shares valued $1,746,000 after scooping up an extra 68,990 shares through out the quarter. Editas Medicine, Inc. (NASDAQ:EDIT) is 4.44% above its 200-day moving average, providing a measure of resistance for long positions. Unusual volume can be a major signal that investment gurus and momentum traders are piling into a stock ahead of a catalyst.
The company has a one year high of $29.20 and a one year low of $12.43. This change led market cap to move at $823.90M, putting the price -32.47% below the 52-week high and 58.65% above the 52-week low.